✦ LIBER ✦

Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies

✍ Scribed by Zhang, Da; Mita, Monica; Shapiro, Geoffrey I.; Poon, Jennifer; Small, Karen; Tzontcheva, Anjela; Kantesaria, Bhavna; Zhu, Yali; Bannerji, Rajat; Statkevich, Paul

Book ID: 120469527
Publisher: Springer
Year: 2012
Tongue: English
Weight: 322 KB
Volume: 70
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-012-1967-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cyclin-Dependent Kinase Inhibitor Dinaci

Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains

✍ Martin, Mathew P.; Olesen, Sanne H.; Georg, Gunda I.; Schönbrunn, Ernst 📂 Article 📅 2013 🏛 American Chemical Society 🌐 English ⚖ 1020 KB

Randomized Phase II Trial of the Cyclin-

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

✍ Mita, Monica M.; Joy, Anil A.; Mita, Alain; Sankhala, Kamalesh; Jou, Ying-Ming; 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 369 KB

A first-in-human, phase 1, dose-escalati

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

✍ Nemunaitis, John J; Small, Karen A; Kirschmeier, Paul; Zhang, Da; Zhu, Yali; Jou 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 353 KB

Phase I evaluation of seliciclib (R-rosc

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

✍ Christophe Le Tourneau; Sandrine Faivre; Valérie Laurence; Catherine Delbaldo; K 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 378 KB

Clinical and laboratory studies of the n

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

✍ Gojo, Ivana; Sadowska, Mariola; Walker, Alison; Feldman, Eric J.; Iyer, Swaminat 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 758 KB

Phase I study of the safety, tolerabilit

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

✍ Glen J. Weiss, Manuel Hidalgo, Mitesh J. Borad, Daniel Laheru, Raoul Tibes, Rame 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 393 KB